Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia.
暂无分享,去创建一个
[1] S. Hunger,et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. , 2008, Blood.
[2] D. Campana,et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. , 2012, Blood.
[3] Elaine Coustan-Smith,et al. A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome. , 2006, Blood.
[4] J. V. van Dongen,et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. , 2010, Blood.
[5] J. Soulier,et al. Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion , 2013, Haematologica.
[6] P. Gaynon,et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. ASBMT Position Statement. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[7] M. Relling,et al. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? , 2012, Blood.
[8] J. Downing,et al. Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] R. Wade,et al. Outcome for children and young people with Early T‐cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003 , 2014, British journal of haematology.
[10] D. Campana,et al. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. , 2010, Blood.
[11] Maria Grazia Valsecchi,et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] G. Lucchini,et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study , 2012, The Lancet. Oncology.
[13] Elaine Coustan-Smith,et al. New markers for minimal residual disease detection in acute lymphoblastic leukemia. , 2011, Blood.
[14] G. Janossy,et al. Immunological monitoring of residual disease in treated thymic acute lymphoblastic leukaemia. , 1981, Leukemia research.
[15] S. Shurtleff,et al. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome‐positive acute lymphoblastic leukemia , 2014, Cancer.
[16] D. Campana,et al. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] R. Wade,et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. , 2013, The Lancet. Oncology.
[18] J. Downing,et al. Improved prognosis for older adolescents with acute lymphoblastic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M. Loh,et al. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. , 2015, Blood.
[20] R. Wade,et al. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. , 2014, The Lancet. Oncology.
[21] K. Schmiegelow,et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia , 2010, Leukemia.
[22] M. Schrappe,et al. Reduced Intensity Delayed Intensification in Standard-Risk Patients Defined By Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: Results of an International Randomized Trial in 1164 Patients (Trial AIEOP-BFM ALL 2000) , 2016 .
[23] Dario Campana,et al. Minimal residual disease monitoring in childhood acute lymphoblastic leukemia , 2012, Current opinion in hematology.
[24] R. Pieters,et al. Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] J. V. van Dongen,et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. , 2011, Blood.
[26] D. Campana,et al. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. , 1995, Blood.
[27] C. Pui,et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia. , 2012, The New England journal of medicine.
[28] Cheng Cheng,et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. , 2009, The Lancet. Oncology.
[29] M. Geyer,et al. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. , 2016, Blood.
[30] J. Downing,et al. Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels. , 2015, Blood.
[31] J. Downing,et al. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. , 2015, The Lancet. Oncology.
[32] Hermann Einsele,et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] D. Campana,et al. Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation , 2013, British journal of haematology.
[34] N. Heerema,et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031 , 2014, Leukemia.
[35] Heather L. Mulder,et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. , 2014, The New England journal of medicine.
[36] J. Downing,et al. Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] Cheng Cheng,et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. , 2009, The New England journal of medicine.
[38] C. Mullighan,et al. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] Quentin Lecrevisse,et al. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. , 2017, Blood.
[40] C. Harrison,et al. EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications. , 2016, Blood.
[41] Alberto Orfao,et al. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. , 2015, Blood.
[42] M. Valsecchi,et al. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis. , 2016, The Lancet. Haematology.
[43] Pui,et al. Clinical Impact of Minimal Residual Disease in Children with Different Subtypes of Acute Lymphoblastic Leukemia Treated with Response-Adapted Therapy , 2016, Leukemia.